Ranbaxy Drops Out of Battle for Merck KGaA’s Generics Unit

The largest pharma company in India, Ranbaxy Laboratories (Gurgaon) has dropped out of the second round of bidding for German pharma major, Merck KGaA’s generics business unit, according to a series of unconfirmed media reports at CW press time last week. The other companies believed to still be in the race for the generic unit are Teva Pharmaceuticals (Petach Tikva, Israel), Actavis (Reykjavik, Iceland), and Mylan Laboratories (Pittsburgh). The estimated worth of Merck’s generics business is around $6 billion, industry sources say. Ranbaxy declined...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers